Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy.
Nelli F, Panichi V, Fabbri A, Natoni F, Giannarelli D, Topini G, Virtuoso A, Giron Berrios JR, Marrucci E, Pessina G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: natoni f. Cancer Invest. 2022 Sep;40(8):710-721. doi: 10.1080/07357907.2022.2092635. Epub 2022 Jun 26. Cancer Invest. 2022. PMID: 35736808
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM, Nelli F, Fabbri A, Onorato A, Giannarelli D, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Panichi V, Pessina G, Signorelli C, Chilelli MG, Primi F, Natoni F, Fazio S, Silvestri MA. Ruggeri EM, et al. Among authors: natoni f. ESMO Open. 2022 Feb;7(1):100350. doi: 10.1016/j.esmoop.2021.100350. Epub 2021 Nov 27. ESMO Open. 2022. PMID: 34942438 Free PMC article.
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A, Panichi V, Topini G, Pessina G, Natoni F, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: natoni f. Ann Oncol. 2022 Jul;33(7):740-742. doi: 10.1016/j.annonc.2022.04.002. Epub 2022 Apr 9. Ann Oncol. 2022. PMID: 35413398 Free PMC article. No abstract available.
Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis.
Signorelli C, Amodio PM, Chilelli MG, Santoro R, Schirripa M, Ranalli TV, Pessina G, Giron Berrios JR, Natoni F, Virtuoso A, Primi F, Mazzotta M, Nelli F, Fabbri A, Marrucci E, Ruggeri EM. Signorelli C, et al. Among authors: natoni f. Cureus. 2022 Oct 23;14(10):e30607. doi: 10.7759/cureus.30607. eCollection 2022 Oct. Cureus. 2022. PMID: 36299600 Free PMC article.
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Pessina G, Natoni F, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: natoni f. Curr Oncol. 2023 May 17;30(5):5103-5115. doi: 10.3390/curroncol30050386. Curr Oncol. 2023. PMID: 37232844 Free PMC article.
Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation.
Poscente M, Tolomeo D, Arshadi A, Agostini A, L'Abbate A, Solimando AG, Palumbo O, Carella M, Palumbo P, González T, Hernández-Rivas JM, Bassi L, Isidori R, Dell'Aquila M, Trapè G, Latagliata R, Pessina G, Natoni F, Storlazzi CT. Poscente M, et al. Among authors: natoni f. Cancer Genet. 2024 Mar 7;284-285:5-11. doi: 10.1016/j.cancergen.2024.03.002. Online ahead of print. Cancer Genet. 2024. PMID: 38471404
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features.
Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F, Di Febo A, Scambia G, Manfredini R, Salati S, Ferrari S, Pierelli L, Leone G, Lemoli RM. Rutella S, et al. Among authors: natoni f. Blood. 2006 Jul 1;108(1):218-27. doi: 10.1182/blood-2005-08-3141. Epub 2006 Mar 9. Blood. 2006. PMID: 16527888 Free article.